---
document_datetime: 2025-12-02 05:48:52
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-hospira.html
document_name: bortezomib-hospira.html
version: success
processing_time: 0.1362787
conversion_datetime: 2025-12-28 11:43:02.655332
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Bortezomib Hospira

[RSS](/en/individual-human-medicine.xml/65427)

##### Authorised

This medicine is authorised for use in the European Union

bortezomib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Bortezomib Hospira](#news-on)
- [More information on Bortezomib Hospira](#more-information-on-bortezomib-hospira-968)
- [Related information](#related-information-437)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Bortezomib Hospira. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Bortezomib Hospira.

For practical information about using Bortezomib Hospira, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Bortezomib Hospira and what is it used for?

Bortezomib Hospira is a cancer medicine used to treat multiple myeloma, a blood cancer, in the following groups of patients:

- adults whose disease is getting worse after at least one other treatment and who have already had, or cannot undergo, blood stem-cell transplantation. Bortezomib Hospira is either used on its own in these patients or in combination with pegylated liposomal doxorubicin or dexamethasone;
- previously untreated adults who cannot have high-dose chemotherapy with blood stem-cell transplantation. In these patients, Bortezomib Hospira is used in combination with melphalan and prednisone;
- previously untreated adults who are going to receive high-dose chemotherapy followed by blood stem-cell transplantation. In this group of patients, Bortezomib Hospira is used in combination with dexamethasone, or with dexamethasone plus thalidomide.

Bortezomib Hospira is also used to treat mantle cell lymphoma, another blood cancer, in untreated adults who cannot have blood stem-cell transplantation. For mantle cell lymphoma, Bortezomib Hospira is used in combination with rituximab, cyclophosphamide, doxorubicin and prednisone.

Bortezomib Hospira is a 'generic medicine'. This means that Bortezomib Hospira is similar to a 'reference medicine' already authorised in the European Union (EU) called Velcade.

Bortezomib Hospira contains the active substance bortezomib.

## How is Bortezomib Hospira used?

The medicine can only be obtained with a prescription and treatment should only be started and given under the supervision of a doctor who has experience in the use of cancer chemotherapy.

Bortezomib Hospira is available in vials as a 3.5 mg powder to be made up into a solution for injection into a vein or under the skin. Bortezomib Hospira must not be given by other routes.

The recommended dose is calculated using the patient's height and weight. When given into a vein, the solution is injected through a catheter (a thin sterile tube). At least 72 hours must pass between two doses of Bortezomib Hospira. When injected under the skin, it is given in the thigh or abdomen (tummy).

Doses of Bortezomib Hospira are given with rest periods between doses, in treatment cycles of three to six weeks depending on whether Bortezomib Hospira is given alone or in combination with other medicines. If a patient develops severe side effects, treatment must be discontinued, delayed or the dose adjusted.

Patients with moderate or severe liver problems should be treated with lower doses. For more information on the use of Bortezomib Hospira see the summary of product characteristics (also part of the EPAR).

## How does Bortezomib Hospira work?

The active substance in Bortezomib Hospira, bortezomib, is a proteasome inhibitor. It blocks proteasome, which is a system in cells that breaks down proteins that are no longer needed. Blocking the proteasome system causes the cell to die. Cancer cells are more sensitive than normal cells to the effects of proteasome inhibitors like bortezomib.

## How has Bortezomib Hospira been studied?

The company provided data from the published literature on bortezomib. No additional studies were needed as Bortezomib Hospira is a generic medicine that is given by injection and contains the same active substance as the reference medicine, Velcade.

## What are the benefits and risks of Bortezomib Hospira?

Because Bortezomib Hospira is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Bortezomib Hospira approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Bortezomib Hospira has been shown to be comparable to Velcade. Therefore, the CHMP's view was that, as for Velcade, the benefit outweighs the identified risk. The Committee recommended that Bortezomib Hospira be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Bortezomib Hospira?

The company that markets Bortezomib Hospira will supply educational material to healthcare professionals on making up and giving the injection, calculating the dose, and prescribing and giving the correct treatment for patients receiving blood stem-cell transplantation.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Bortezomib Hospira have also been included in the summary of product characteristics and the package leaflet.

## Other information about Bortezomib Hospira

The European Commission granted a marketing authorisation valid throughout the European Union for Bortezomib Hospira on 22 July 2016.

For more information about treatment with Bortezomib Hospira, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Bortezomib Hospira : EPAR - Summary for the public

Reference Number: EMA/CHMP/380101/2016

English (EN) (99.11 KB - PDF)

**First published:** 29/07/2016

**Last updated:** 29/07/2016

[View](/en/documents/overview/bortezomib-hospira-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-567)

български (BG) (126.38 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/bg/documents/overview/bortezomib-hospira-epar-summary-public_bg.pdf)

español (ES) (99.23 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/es/documents/overview/bortezomib-hospira-epar-summary-public_es.pdf)

čeština (CS) (124.01 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/cs/documents/overview/bortezomib-hospira-epar-summary-public_cs.pdf)

dansk (DA) (98.62 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/da/documents/overview/bortezomib-hospira-epar-summary-public_da.pdf)

Deutsch (DE) (100.4 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/de/documents/overview/bortezomib-hospira-epar-summary-public_de.pdf)

eesti keel (ET) (97.65 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/et/documents/overview/bortezomib-hospira-epar-summary-public_et.pdf)

ελληνικά (EL) (128.08 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/el/documents/overview/bortezomib-hospira-epar-summary-public_el.pdf)

français (FR) (100.01 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/fr/documents/overview/bortezomib-hospira-epar-summary-public_fr.pdf)

hrvatski (HR) (117.97 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/hr/documents/overview/bortezomib-hospira-epar-summary-public_hr.pdf)

italiano (IT) (98.25 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/it/documents/overview/bortezomib-hospira-epar-summary-public_it.pdf)

latviešu valoda (LV) (119.47 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/lv/documents/overview/bortezomib-hospira-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (120.53 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/lt/documents/overview/bortezomib-hospira-epar-summary-public_lt.pdf)

magyar (HU) (116.32 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/hu/documents/overview/bortezomib-hospira-epar-summary-public_hu.pdf)

Malti (MT) (123.22 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/mt/documents/overview/bortezomib-hospira-epar-summary-public_mt.pdf)

Nederlands (NL) (98.88 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/nl/documents/overview/bortezomib-hospira-epar-summary-public_nl.pdf)

polski (PL) (124 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/pl/documents/overview/bortezomib-hospira-epar-summary-public_pl.pdf)

português (PT) (99.33 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/pt/documents/overview/bortezomib-hospira-epar-summary-public_pt.pdf)

română (RO) (119.82 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/ro/documents/overview/bortezomib-hospira-epar-summary-public_ro.pdf)

slovenčina (SK) (122.62 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/sk/documents/overview/bortezomib-hospira-epar-summary-public_sk.pdf)

slovenščina (SL) (116.17 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/sl/documents/overview/bortezomib-hospira-epar-summary-public_sl.pdf)

Suomi (FI) (97.69 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/fi/documents/overview/bortezomib-hospira-epar-summary-public_fi.pdf)

svenska (SV) (98.5 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

29/07/2016

[View](/sv/documents/overview/bortezomib-hospira-epar-summary-public_sv.pdf)

Bortezomib Hospira : EPAR - Risk-management-plan summary

English (EN) (77.28 KB - PDF)

**First published:** 19/10/2020

[View](/en/documents/rmp-summary/bortezomib-hospira-epar-risk-management-plan-summary_en.pdf)

## Product information

Bortezomib Hospira : EPAR - Product Information

English (EN) (588.89 KB - PDF)

**First published:** 29/07/2016

**Last updated:** 16/05/2025

[View](/en/documents/product-information/bortezomib-hospira-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-790)

български (BG) (422.67 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/bg/documents/product-information/bortezomib-hospira-epar-product-information_bg.pdf)

español (ES) (568.02 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/es/documents/product-information/bortezomib-hospira-epar-product-information_es.pdf)

čeština (CS) (451.55 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/cs/documents/product-information/bortezomib-hospira-epar-product-information_cs.pdf)

dansk (DA) (398.47 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/da/documents/product-information/bortezomib-hospira-epar-product-information_da.pdf)

Deutsch (DE) (417.67 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/de/documents/product-information/bortezomib-hospira-epar-product-information_de.pdf)

eesti keel (ET) (381.28 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/et/documents/product-information/bortezomib-hospira-epar-product-information_et.pdf)

ελληνικά (EL) (431.16 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/el/documents/product-information/bortezomib-hospira-epar-product-information_el.pdf)

français (FR) (407.11 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/fr/documents/product-information/bortezomib-hospira-epar-product-information_fr.pdf)

hrvatski (HR) (372.75 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/hr/documents/product-information/bortezomib-hospira-epar-product-information_hr.pdf)

íslenska (IS) (397.06 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/is/documents/product-information/bortezomib-hospira-epar-product-information_is.pdf)

italiano (IT) (381.81 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/it/documents/product-information/bortezomib-hospira-epar-product-information_it.pdf)

latviešu valoda (LV) (388.61 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/lv/documents/product-information/bortezomib-hospira-epar-product-information_lv.pdf)

lietuvių kalba (LT) (402.14 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/lt/documents/product-information/bortezomib-hospira-epar-product-information_lt.pdf)

magyar (HU) (411.97 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/hu/documents/product-information/bortezomib-hospira-epar-product-information_hu.pdf)

Malti (MT) (504.55 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/mt/documents/product-information/bortezomib-hospira-epar-product-information_mt.pdf)

Nederlands (NL) (428 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/nl/documents/product-information/bortezomib-hospira-epar-product-information_nl.pdf)

norsk (NO) (391.86 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/no/documents/product-information/bortezomib-hospira-epar-product-information_no.pdf)

polski (PL) (436.78 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/pl/documents/product-information/bortezomib-hospira-epar-product-information_pl.pdf)

português (PT) (380.17 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/pt/documents/product-information/bortezomib-hospira-epar-product-information_pt.pdf)

română (RO) (902.93 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/ro/documents/product-information/bortezomib-hospira-epar-product-information_ro.pdf)

slovenčina (SK) (405.76 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/sk/documents/product-information/bortezomib-hospira-epar-product-information_sk.pdf)

slovenščina (SL) (394.94 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/sl/documents/product-information/bortezomib-hospira-epar-product-information_sl.pdf)

Suomi (FI) (393 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/fi/documents/product-information/bortezomib-hospira-epar-product-information_fi.pdf)

svenska (SV) (402.59 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

16/05/2025

[View](/sv/documents/product-information/bortezomib-hospira-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000263654 16/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Bortezomib Hospira : EPAR - All Authorised presentations

English (EN) (30.83 KB - PDF)

**First published:** 29/07/2016

**Last updated:** 18/02/2019

[View](/en/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-46)

български (BG) (37.48 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/bg/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_bg.pdf)

español (ES) (34.62 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/es/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_es.pdf)

čeština (CS) (35.4 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/cs/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (35.14 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/da/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (37.39 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/de/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (34.12 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/et/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (37.12 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/el/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_el.pdf)

français (FR) (32.82 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/fr/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (30.14 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/hr/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (35.53 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/is/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_is.pdf)

italiano (IT) (29.68 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/it/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (30.5 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/lv/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (30.92 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/lt/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (35.24 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/hu/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (30.31 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/mt/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (29.36 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/nl/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (30.13 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/no/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_no.pdf)

polski (PL) (30.92 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/pl/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_pl.pdf)

português (PT) (30.58 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/pt/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_pt.pdf)

română (RO) (30.62 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/ro/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (28.59 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/sk/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (29.81 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/sl/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (33.66 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/fi/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (30.15 KB - PDF)

**First published:**

29/07/2016

**Last updated:**

18/02/2019

[View](/sv/documents/all-authorised-presentations/bortezomib-hospira-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Bortezomib Hospira Active substance bortezomib International non-proprietary name (INN) or common name bortezomib Therapeutic area (MeSH) Multiple Myeloma Anatomical therapeutic chemical (ATC) code L01XG01

### Pharmacotherapeutic group

Other antineoplastic agents

### Therapeutic indication

Bortezomib Hospira as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.

Bortezomib Hospira in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.

Bortezomib Hospira in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.

Bortezomib Hospira in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

## Authorisation details

EMA product number EMEA/H/C/004207

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Opinion adopted 26/05/2016 Marketing authorisation issued 22/07/2016 Revision 14

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Bortezomib Hospira : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (143.15 KB - PDF)

**First published:** 16/05/2025

[View](/en/documents/procedural-steps-after/bortezomib-hospira-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Bortezomib Hospira : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (132.02 KB - PDF)

**First published:** 09/03/2017

**Last updated:** 16/05/2025

[View](/en/documents/procedural-steps-after/bortezomib-hospira-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Bortezomib Hospira-H-C-PSUSA-00000424-202004 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/122201/2021

English (EN) (129.71 KB - PDF)

**First published:** 24/03/2021

[View](/en/documents/scientific-conclusion/bortezomib-hospira-h-c-psusa-00000424-202004-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Bortezomib Hospira-H-C-PSUSA-00000424-201804 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/169116/2019

English (EN) (66.7 KB - PDF)

**First published:** 21/03/2019

[View](/en/documents/scientific-conclusion/bortezomib-hospira-h-c-psusa-00000424-201804-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Bortezomib Hospira : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/421198/2016

English (EN) (289.81 KB - PDF)

**First published:** 29/07/2016

**Last updated:** 29/07/2016

[View](/en/documents/assessment-report/bortezomib-hospira-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Bortezomib Hospira

Adopted

Reference Number: EMA/CHMP/327595/2016

English (EN) (77.21 KB - PDF)

**First published:** 27/05/2016

**Last updated:** 27/05/2016

[View](/en/documents/smop-initial/chmp-summary-opinion-bortezomib-hospira_en.pdf)

#### News on Bortezomib Hospira

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 May 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-may-2016) 27/05/2016

#### More information on Bortezomib Hospira

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Related information

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/search?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-1=1=EMEAHC0042070000) (initial marketing authorisation)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 16/05/2025

## Share this page

[Back to top](#main-content)